Cancer vaccines and immune-activating (agonistic) immunotherapies harbor the potential to induce specific anti-tumor immune responses against any tumor antigen of interest, presented by major histocompatibility complex (MHC), which complement checkpoint inhibitors. The gene discussed is HLA-C; the disease is neoplasm.